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Innate lymphoid cells (ILCs) are emerging key players of the immune system with close
lineage relationship to T cells. ILC2 play an important role in protective immunity against
multicellular parasites, but are also involved in the pathogenesis of type 2 immune dis-
eases. Here, we have studied the developmental requirements for human ILC2. We report
that ILC2 are present in the thymus of young human donors, possibly reflecting local differ-
entiation. Furthermore, we show that uncommitted lineage−CD34+CD1a− human thymic
progenitors have the capacity to develop into ILC2 in vitro under the influence of Notch
signaling, either by stimulation with the Notch ligand Delta like 1 (Dll1) or by expression
of the active intracellular domain of NOTCH1 (NICD1). The capacity of NICD1 to mobilize
the ILC2 differentiation program was sufficiently potent to override commitment to the T
cell lineage in CD34+CD1a+ progenitors and force them into the ILC2 lineage. As Notch is
an important factor also for T cell development, these results raise the question how one
and the same signaling pathway can elicit such distinct developmental outcomes from the
same precursors. We provide evidence that Notch signal strength is a critical determinant
in this decision: by tuning signal amplitude, Notch can be converted from a T cell inducer
(low signal strength) to an ILC2 inducer (high signal strength). Thus, this study enhances
our understanding of human ILC2 development and identifies a mechanism determining
specificity of Notch signal output during T cell and ILC2 differentiation.
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INTRODUCTION
A new group of hematopoietic effector cells has been identified
in recent years, which is now commonly referred to as the innate
lymphoid cell (ILC) family (1). Cells belonging to this family char-
acteristically express the IL7Rα chain (CD127), but lack markers
specific for any other hematopoietic lineage. Members of this fam-
ily are closely related to T cells, but do not express rearranged
antigen receptors (2).
The ILC family displays broad functional diversity, which strik-
ingly resembles that of T cells in terms of activating stimuli and
signature cytokines secreted. For every T helper cell lineage, there
appears to be a corresponding ILC lineage: group 1 ILC produce
IFNγ like T helper 1 cells (Th1) (3–5), ILC2 produce Interleukin
5 (IL-5) and IL-13 and are thus akin to Th2 cells (6–9), and mem-
bers of the ILC3 lineage produce IL-17 and/or IL-22, resembling
Th17 and Th22 cells (10–12). ILC secrete these factors in response
to cytokines produced by epithelial and myeloid cells upon stress
inflicted by pathogens. For instance, type 2 ILC respond to IL-
25, IL-33, and thymic stromal lymphopoetin (TSLP), which are
secreted by mast cells and epithelial cells (13). ILC2 are crucial
for defense against helminth parasites (6) and involved in airway
inflammation and tissue repair associated with influenza infec-
tions (14, 15). Accumulating evidence also implicates ILC2 in
the pathogenesis of type 2 inflammatory diseases such as allergic
asthma (16–20).
Like T cells, ILC2 are known to derive from a common lym-
phoid progenitor (CLP) (21–23). While developmental processes
of ILC are only beginning to be explored, differentiation of T
cells has been well characterized. T cell differentiation is initiated
after migration of CLP to the thymus, the primary site of T cell
development. Developing human T cells can be separated into sev-
eral discrete stages. The earliest thymic progenitors express CD34,
but lack expression of CD7 and CD1a (24, 25). These cells have
been shown to retain myeloid potential in vitro (26), whereas CD7
upregulation restricts them to NK/T potential. Commitment to
the T cell lineage is marked by upregulation of CD1a (25). This
is followed by rearrangement of T cell receptor β genes. Once a
fully rearranged in frame TCRβ gene is generated, its gene product
combines with the pre-TCRα chain (pTα) to form the pre-TCR,
allowing a process called β-selection to take place. In humans,
TCRβ+ cells first appear at an immature CD4+ stage (ISP4+)
stage (27). As a consequence of β-selection, cells expand massively,
(further) upregulate CD4 and CD8 co-receptors and rearrange
their TCRα genes to generate the mature TCR, which is subjected
to positive and negative selection processes. Final differentiation
of T cells into effector cells, such as Th1, Th2, or Th17 cells, does
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not occur until the cells are activated by cognate antigen in the
secondary lymphoid organs.
Aside from the absence of antigen receptors, ILC clearly are
distinct from T cells in their developmental requirements. Thus,
ILC lineages depend on Id2 for their development, whereas this
factor is dispensable for T cell development. Also, the factor RORα
is essential for differentiation of ILC2 cells, but is not required
for development of the corresponding Th2 subset, at least in vitro
(20). Nonetheless, many parallels do exist between the factors that
regulate differentiation of the various Th subsets and their ILC
counterparts. For instance, RORγt is required for generation of
(murine) Th17 and group 3 ILCs (28), whereas evidence sug-
gests that the lineage defining transcription factor for Th1 cells,
Tbet (29), also regulates ILC1 differentiation (30). ILC2, on the
other hand, depend on GATA3 for development and function, as
do Th2 cells (31–34). Two additional factors known to govern T
cell specification from thymic progenitors were recently shown to
also be required for ILC2 differentiation, namely Tcf1 (35) and
Notch (23).
Notch is a cell surface receptor, which is activated by binding
to membrane bound ligands of the Delta like (Dll1 and Dll4) and
Jagged (Jagged 1, Jagged 2) families. Ligand binding initiates a
proteolytic cascade, which results in the release of the intracellular
portion of the receptor, the Notch intracellular domain (NICD).
NICD then translocates to the nucleus, where it associates with the
DNA binding factor CSL [named after CBF-1 (mammals), Su(H)
(Drosophila), and Lag-1 (C. elegans)]. Together, NICD and CSL
recruit additional coactivators to induce transcription of target
genes (36).
Notch signaling is absolutely required for at least two steps
during the differentiation of T cells: T cell commitment and
β-selection. The Notch pathway has also been implicated in dif-
ferentiation of ILC (37). Lymphoid tissue inducer cells (LTi),
which belong to the ILC3 group (1), require transient Notch
activity at an early stage but Notch needs to be downregulated
to allow for further differentiation of these cells (38). Depending
on the microenvironment, Natural Cytotoxicity Receptor (NCR)+
ILC3 (named according to the expression of the NCR genes
Nkp44/Nkp46) also might develop under the influence of Notch
(39, 40). Finally, murine studies have demonstrated that group 2
ILC require Notch signaling for their development in vitro (23,
35). Whether Notch also regulates differentiation of human ILC2
has not been examined.
The involvement of Notch in differentiation of both ILC2
and T cells raises the question how activation of these pathways
results in adoption of the T cell versus the ILC2 differentiation
program. Two fundamentally different mechanisms are possi-
ble. First, the two cell types develop from different precursors,
already more or less committed to either lineage. Alternatively,
a common precursor gives rise to both cell types. In this sce-
nario, the signals driving differentiation are distinct either quali-
tatively, involving additional signals dedicated to either lineage, or
quantitatively.
Here, we examined these possibilities by studying Notch medi-
ated in vitro differentiation of human thymocytes. We find
that human thymic progenitors can give rise to both T cells
and ILC2 in response to activation of Notch. Our data show
that the strength of the Notch signal determines whether T
cells or ILC2 are generated, with stronger signals favoring ILC2
differentiation. Thereby, we provide a mechanism explaining
how the distinction between the T cell and ILC2 program can
be made.
RESULTS
GROUP 2 INNATE LYMPHOID CELLS CAN BE FOUND IN THE HUMAN
THYMUS
The close lineage relationship between T cells and group 2 ILCs
(35) suggests that common precursors may exist for both lineages,
which, depending on microenvironmental signals, differentiate
into either T cells or ILC2. T cells differentiate in the thymus.
Where ILC2 develop has not been established. There is evidence
that these cells are generated in other locations than thymus, as
suggested by the discovery of an ILC2 precursor in bone mar-
row (32, 41) and the presence of ILC2 in athymic FoxN1nu/nu
(nude) mice (23, 42). However, these findings do not exclude the
possibility that ILC2 can be generated in the thymus as well. If
common precursors of ILC2 and T cells exist, which differentiate
into ILC2 in the thymus, one would expect to find differen-
tiated ILC2 in this organ. To examine this, we analyzed single
cell suspensions of freshly isolated human thymocytes by multi-
color flow cytometry for markers associated with group 2 ILC.
ILCs were defined as CD45+ cells expressing high levels of the
IL7Rα chain (CD127), but lacking expression of markers spe-
cific for T cells (CD1a, CD3, TCRγδ, TCRαβ), B cells (CD19),
hematopoietic stem cells (CD34), and other lineages (CD11c,
CD14, CD94, CD123, FcεR1, BDCA2), collectively termed “lin-
eage” (Figure 1A, left). We found that an average of 0.0625% of
CD45+ thymocytes belong to the ILC lineages. We further ana-
lyzed these IL7Rαhighlineage− cells for the expression of CRTH2
(Figure 1A, right), which, within the family of ILCs, is specific
for group 2 ILC (9). Using this strategy, we indeed detected a dis-
tinct population of CRTH2+ ILC in thymic specimens, on average
accounting for 5% of the lineage−IL7Rαhigh ILC compartment
(Figure 1C).
Phenotypically, thymic lineage−IL7RαhighCRTH2+ cells are
similar to group 2 ILCs identified in other human tissues in that
they express CD161 (9) and cKit (CD117) (Figure 1B), as was
described for a subpopulation of human ILC2 (1). Furthermore,
thymic lineage−IL7RαhighCRTH2+ cells do not express CD56 or
NKp44 (Figure 1B), which are associated with conventional NK
cells and ILC3 (1). These cells therefore adhere to what have been
defined as the phenotypic hallmarks of human group 2 ILC (2, 9)
and can thus be regarded as thymic ILC2.
The presence of ILC2 in the thymus is remarkable, because thus
far, such cells have only been found in mucosal tissues in the intes-
tine and airways, consistent with their role in innate border patrol,
in blood (9), presumably reflecting their migration, and in bone
marrow, the major site of hematopoiesis (8, 34). Although we did
not formally test whether ILC2 differentiation takes place in the
human thymus, the fact that such cells are found at relatively high
numbers in the thymus is consistent with the possibility that these
cells are generated in this non-inflamed organ.
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FIGURE 1 | Human thymus contains group 2 innate lymphoid cells.
(A) Gating strategy applied to identify thymic ILC2. Thymocytes were
pre-gated for CD45+ cells and innate lymphoid cells were defined as
lineage− (CD1a−CD3−CD11c−CD14−CD19−CD34−CD123−TCRαβ−TCRγδ−
BDCA2−FcεRI−) CD127high cells (left). This population was further analyzed
for the presence of CRTH2+ cells (right). Percentages of cells in the
respective gates are displayed. (B) Flow cytometric analysis of the
expression of CD161, CD117 (cKit), Nkp44, and CD56 by thymic ILC2 as
defined in (A). Representative FACS plots from a single donor are shown
(A,B). (C) Relative abundance of ILC2 in human thymic specimens from a
total of 16 donors analyzed (C). Results in (C) are shown as mean±SEM.
IN VITRO DIFFERENTIATION OF ILC2 FROM THYMIC PROGENITORS BY
NOTCH SIGNALING
Given the presence of innate group 2 lymphocytes in the human
thymus, we asked whether these cells can develop directly from
thymic progenitors. A recent study showed that ILC2 differentia-
tion can be induced from murine bone marrow-derived common
lymphoid and thymic progenitors by co-culture with OP9 stromal
cells expressing the Notch ligand Dll1 (23). To test whether human
thymic progenitors have the capacity to differentiate into ILC2, we
initiated OP9 co-cultures with human CD34+CD1a− thymocytes,
which have not yet committed to the T lineage (43). Although some
lineage−IL7Rα+CRTH2+ cells appeared after 1 week of culture
with control OP9 cells, the frequency of such cells was significantly
increased upon co-culture with OP9 Dll1 (Figure 2A). Under these
same conditions, OP9 Dll1 cells also induced differentiation of T
cells, as expected, but this process required minimally 2 weeks of
co-culture (Figure 2B).
Interestingly, when OP9 Dll1 co-cultures were initiated with
thymic CD34+CD1a+ progenitors, which are believed to already
have committed to the T cell lineage (43), enhanced induction
of lineage−IL7Rα+CRTH2+ cells by OP9 Dll1 was not detected
(Figure 2C). This indicates that these progenitors might have lost
the potential to differentiate into the ILC lineage, as has been
demonstrated for murine thymic DN3 cells (23).
CONSTITUTIVE NOTCH1 ACTIVATION ROBUSTLY INDUCES
DIFFERENTIATION OF LINEAGE−IL7Rα+CRTH2+ CELLS
OP9 cells expressing Dll1 have widely been used to induce Notch
dependent T cell differentiation (44). It is not immediately obvi-
ous how activation of Notch in the same progenitors would
induce two distinct differentiation programs, namely ILC2 or
T cells. Although Notch is clearly required in a cell intrinsic
manner in thymic progenitors during T cell differentiation (45),
this has not been established for ILC2. Indeed, it is conceiv-
able that ILC2 induction by OP9 Dll1 would be an indirect
effect from lateral Notch activation in the OP9 cells, resulting
in production of other signals by these cells, which promote
ILC2 differentiation. To test whether cell intrinsic Notch signaling
in thymic progenitors induces ILC2 differentiation, we ectopi-
cally expressed the intracellular domain of NOTCH1 (NICD1)
in thymic CD34+CD1a− progenitors, thereby inducing constitu-
tive activation of NOTCH1 in these cells, and subjected these to
co-culture on control OP9 cells. NICD1 expression resulted in
robust induction of an IL7Rα+CRTH2+ population, which lacks
expression of T cell (CD1a, CD3, CD4, CD8, TCRαβ, TCRγδ) and
other lineage markers (CD11c, CD14, CD19, CD34, CD94, CD123,
FcεR1, BDCA2) (Figure 3A). Thus, direct activation of Notch in
thymic CD34+CD1a− progenitors results in the differentiation of
cells resembling ILC2 cells.
A prominent population of lineage−CRTH2+ cells was usu-
ally present after 1 week, but these cells first appeared after
as little as 4 days of co-culture on OP9 cells, and persisted
for up to 2 weeks (Figure 3B). NICD1 induced differentia-
tion of lineage−IL7Rα+CRTH2+ cells was subject to donor-
to-donor variation. However, ectopic NICD1 expression consis-
tently induced a prominent lineage−IL7Rα+CRTH2+ population
(Figure 3C).
Strikingly, NICD1 even robustly induced a lineage−IL7Rα+
CRTH2+ population from T-committed CD34+CD1a+ thymic
progenitors, although to a lesser degree than from uncommitted
CD34+CD1a− thymocytes (compare Figures 3C,D). This suggests
that strong, sustained Notch signaling can overcome commitment
to the T cell lineage in thymic progenitors and therefore challenges
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FIGURE 2 |Thymic progenitors can differentiate into ILC2 in vitro by
Notch activation. (A) Flow cytometric analysis of ILC2 differentiation from
thymic CD34+CD1a− progenitors. Cells were cultured on control OP9 or OP9
Dll1 as indicated for 1 week. ILC2 were defined as CD45+ lineage−CRTH2+.
(B) CD34+CD1a− progenitors were cultured on OP9 cells as indicated. After
2 weeks, the abundance of CD4+CD8+ T cells was assessed. (C)Thymic
CD34+CD1a+ progenitors were cultured and ILC2 development was
measured as in (A). Data are shown as mean±SEM from minimally four
independent experiments. Mann–Whitney test was performed for statistical
analyses, *p<0.05.
the lineage fidelity of these precursors. Strikingly, ectopic expres-
sion of NICD1 in CD34+CD1a− thymocytes also resulted in
a prominent lineage−IL7Rα+CRTH2+ population when thymic
progenitors were cultured in the combined presence of IL-7 and
Flt3l (Figure 3E), conditions known to promote development into
the T cell lineage (46, 47).
Collectively, these data show that activation of Notch in human
thymic hematopoietic progenitors activates the ILC2 differentia-
tion program. Indeed, the connection between Notch and the ILC2
differentiation program is potent enough to dismantle the T cell
differentiation program in cells already committed to the T cell
lineage and make them adopt the ILC2 fate instead.
The transcription factor GATA3 has been shown to play an
essential role in development and function of both murine and
human ILC2 (32, 33). Overexpression of GATA3 in a population
of lineage−CD127+CD117+Nkp44−CRTH2− immature ILC was
sufficient to drive these cells into the ILC2 lineage (33). To deter-
mine whether GATA3 is also able to elicit ILC2 differentiation from
thymic progenitors, we ectopically expressed this factor from a
retroviral vector in CD34+CD1a− uncommitted progenitors and
monitored ILC2 differentiation. Indeed, GATA3 expression was
sufficient to induce an ILC2 phenotype (Figure 3F), further sup-
porting the notion that thymic progenitors have the capacity to
differentiate into genuine ILCs. However, NICD1 was more potent
in ILC2 differentiation in direct comparison with GATA3,at least at
the expression levels obtained by our retroviral expression systems
(Figure 3F).
NOTCH1 INDUCED CRTH2+ CELLS ARE BONA FIDE ILC2
Thus far, our interpretation that Notch activation instructs thymic
progenitors to differentiate into ILC2 cells has been based on the
absence of lineage markers (including those defining T cells) and
the presence of CRTH2, a marker supposedly not found in imma-
ture T cells. However, given the wealth of data demonstrating the
role of Notch in differentiation of T cells, it is conceivable that the
cells obtained here represent a previously not described subtype of
immature T cells. Also, it is possible that our results reflect atyp-
ical expression of CRTH2 on T cell lineage cells, for instance as
a consequence of direct transactivation of the gene encoding this
marker by Notch. We therefore sought to determine whether the
CRTH2+ cells differentiated from thymic progenitors in response
to Notch are genuine group 2 ILCs.
To this end, we performed more extensive phenotyping by
multi-color flow cytometry, examining the surface expression of
several markers known to be associated with human ILC2. As
described above (Figure 3A), NICD1+ (CRTH2+) cells express the
IL7Rα chain (Figure 4A), although surface levels varied between
experiments and were sometimes lower than those found on
freshly isolated ILCs. This is most likely due to in vitro culture
in the presence of recombinant IL-7, which results in receptor
internalization (48). Indeed, such down regulation of IL7Rα has
also been observed when freshly isolated mature ILC2 cells were
cultured in vitro (9). NICD1 induced CRTH2+ cells express low
levels of KLRB1 (CD161) in a bimodal distribution (Figure 4A)
as has been shown for human ILC derived from other tissues (9).
Additionally, NICD1 induced CRTH2+ cells also express CD25
(the IL-2Rα chain), CD7, and ICOS, all of which have been shown
to be expressed by group 2 ILCs (1, 9). CRTH2+ cells differentiated
in vitro by Notch activation for the most part do not express cKit
(Figure 4A). The interpretation of this observation is complicated
by the fact that expression of cKit by human group 2 ILC is vari-
able. Among human fetal gut and peripheral blood ILC2, both a
cKit+ and cKit− population have been described (9). Expression
of cKit, therefore, does not seem to constitute part of the core
ILC2 identity. Finally, NOTCH1 induced CRTH2+ cells do not
show surface expression of CD56 and Nkp44 (Figure 4A), associ-
ated with the NK and other ILC subsets (1). Taken together, the
expression pattern of these surface markers shows that CRTH2+
cells derived from thymic progenitors by Notch mediated in vitro
differentiation phenotypically resemble bona fide ILC2 found in
the thymus and various other human tissues.
To further characterize these Notch induced thymic ILC2, we
determined mRNA expression levels of lineage defining tran-
scription factors, cytokine receptors, and signature cytokines in
cells directly isolated from differentiation cultures (Figure 4B).
Cells differentiated from thymic progenitors in vitro by expression
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FIGURE 3 | Constitutive activation of Notch induces prominent ILC2
differentiation. (A) Flow cytometric analysis for expression of CD127 and
CRTH2 by thymic CD34+CD1a− progenitors transduced with NICD1 (right) or
an empty vector control (left), both containing IRES-Thy1.1, and cultured on
control OP9 cells. Numbers indicate percentages of CD45+ lineage− cells
expressing CRTH2 among transduced (Thy1.1+) cells. Data shown are from
one representative experiment out of nine experiments. (B)Time course of
ILC2 differentiation induced by ectopic expression of NICD1 (black line) in
CD34+CD1a− thymocytes. CRTH2 expression by transduced CD45+ lineage−
cells after 4 days (left), 1 week (middle), and 2 weeks (right) of co-culture is
shown. Data are representative of two independent experiments. Empty
vector (ev) control transduced cells are shown in light gray lines, filled dark
gray histogram represents staining with an isotype-matched control antibody.
(C,D) Cumulative data from ILC2 differentiation induced by ectopic expression
of NICD1 in CD34+CD1a− (C) and CD34+CD1a+ (D) thymocytes. Shown is
mean±SEM of nine (C) and seven (D) experiments. Significance was
analyzed using the Mann–Whitney test, *p< 0.05, ***p<0.0005.
(E) Differentiation of CD45+ lineage−CRTH2+ cells by CD34+CD1a−
thymocytes cultured in the presence of IL-7 only or IL-7+Flt3l.
(F) Differentiation of CD45+ lineage−CRTH2+ cells by ectopic expression of
NICD1 or GATA3 in CD34+CD1a− thymocytes. Data in (E,F) are shown as
mean+SD from two independent experiments.
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FIGURE 4 | NICD1 induced lineage−CRTH2+ cells are bona fide ILC2.
(A) Flow cytometric analysis of surface expression of CD127 (IL7Rα),
CD117 (cKit), CD161, CD7, CD25, ICOS, CD56, and Nkp44 on Thy1.1+
thymocytes transduced with NICD1-IRES-Thy1.1-MSCV (black line) or
IRES-Thy1.1-MSCV empty vector (ev, gray line) and differentiated in vitro on
control OP9 cells. Gray shaded: isotype-matched control antibody. FACS
data are representative of minimally three experiments. (B) Expression of
PTGDR2 (CRTH2), IL1RL1 (ST2), IL17RB (IL-25R), CRLF2 (TSLP-R), RORA,
GATA3, IL-5, and IL-13 mRNA in thymocytes transduced and differentiated
in vitro as in (A). Cells were sorted after 1 week of culture as NICD1 (red
bars) or empty vector transduced (ev, white bars) on the basis of Thy1.1
expression. Expression levels were normalized to the housekeeping gene
β-Actin. nd, Not detectable. Data are shown as mean+SD of two
independent experiments.
of NICD1 expressed transcripts for the lineage specific cytokine
receptors IL1RL1 (ST2, a subunit of the IL-33 receptor), IL17RB
(a subunit of the receptor for IL-25), and CRLF2 (TSLP-R).
Together with CD25 (Figure 4A), these cells thus express the
critical receptors to respond to the ILC2 activating cytokines IL-
2, IL-25, IL-33, and TSLP. Notably, expression of transcripts for
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these cytokine receptors was not detected in empty vector con-
trol cells (Figure 4B). In vitro differentiated ILC2 also expressed
RORA mRNA encoding the ILC2 lineage specific transcription
factor RORα. However, these cells did not express elevated levels
of GATA3 compared to control cells. This may seem counter-
intuitive, given the ability of GATA3 to induce ILC2 differentiation
from thymic progenitors (Figure 3E) and the fact that GATA3 is
a known direct target of Notch signaling (49–51). However, it
should be noted that expression of GATA3 is low also in resting
ILC2 derived from peripheral tissues after in vitro culture and
that expression of this factor is elevated only after exposure to
activating stimuli such as TSLP (33). Therefore, high constitutive
expression of GATA3 does not seem to be a characteristic of rest-
ing human ILC2 cells. Most strikingly, even without exogenous
activation, NICD1+ cells expressed transcripts for the ILC2 signa-
ture cytokines IL-13 and IL-5 (Figure 4B), whereas empty vector
control cells did not, further reinforcing the interpretation that
NICD1 induced CRTH2+ cells are fully functional group 2 ILC.
Constitutive expression of IL-5 and IL-13 transcripts by unstim-
ulated ILC2 has been observed previously in the fetal gut (9).
We therefore conclude that ILC2 differentiated in vitro from
thymic progenitors by activation of NOTCH1 resemble bona fide
group 2 ILCs.
NOTCH PROMOTES T CELL VERSUS ILC2 DIFFERENTIATION IN A
SIGNAL STRENGTH DEPENDENT MANNER
The fact that activation of Notch can induce differentiation of
both T cells and ILC2 from the same thymic progenitors raises the
question what determines which of these differentiation programs
is turned on. The Notch pathway is sensitive to signal amplitude,
which allows induction of discretely different responses by one
and the same signaling pathway (52, 53). Given our findings that
expression of NICD1 was much more potent at eliciting ILC2 dif-
ferentiation than co-culture with OP9 Dll1, we reasoned that the
strength of the Notch signal might be a critical factor deciding
whether T cells or ILC2 are generated.
To test this hypothesis, we generated an expression construct,
in which the concentration of nuclear NICD1 can be controlled in
a quantitative manner. In this construct, NICD1 is N-terminally
fused to a mutated Estrogen receptor ligand binding domain
(mER). This mutated domain no longer binds Estrogen, but does
respond to Tamoxifen (54). In the absence of this drug, mER-
NICD1 is bound by heat shock proteins in the cytoplasm and
hence kept transcriptionally inactive. Addition of Tamoxifen to the
culture medium induces transcriptional activity of mER-NICD1
in a dose-dependent manner (Figure 5A). Some leakiness is fre-
quently observed with these types of ER-fusion proteins (55, 56)
and indeed, we also consistently observed weak but significant
activity of mER-NICD1 in the absence of Tamoxifen (Mock) on
two different Notch-responsive promoters (Figure 5A). Therefore,
this tool enabled us to induce different levels of NOTCH1 activa-
tion, and even explore the impact of very low levels owing to the
leakiness of the mER system. In comparison, expression of con-
stitutively active NICD1 served to induce high signaling strength.
Together, these constructs allowed us to examine the consequences
of Notch signaling across a more than 100-fold dynamic range, as
measured in reporter gene assays (compare luciferase activities in
the absence of Tamoxifen with those obtained with expression of
constitutively active NICD1 in Figure 5A).
To test whether Notch signal strength affects ILC2/T cell differ-
entiation, we retrovirally expressed mER-NICD1 or constitutive
NICD1 in uncommitted, CD34+CD1a− thymic precursors, sub-
jected these to co-culture on control OP9 cells and titrated in
Tamoxifen. The activity of the mER-NICD1 and NICD1 con-
structs could also be controlled quantitatively in these cells,
as shown by the Tamoxifen dose-dependent induction of CD7
expression (Figure 5B), which we have found to be a sensitive
gauge for Notch activity in thymic precursors.
Using this system, we measured differentiation of T cells as
well as group 2 ILC by flow cytometry. We chose to examine the
development of these cells after 2 weeks because of the different
kinetics in T cell and ILC2 differentiation. Differentiation of T
cells generally requires incubation periods of at least 2 weeks (57)
(Figure 2B). As shown before (Figure 3B), group 2 ILC popula-
tions emerge within several days of culture, but persist longer and
could therefore be assessed here after 2 weeks in direct comparison
with T cells.
As expected, neither T cell differentiation nor generation of
ILC2 occurred effectively in the absence of Notch activation: con-
siderable populations of both CD4+CD8α+ T cells (Figure 5C)
and lineage−IL7Rα+CRTH2+ ILC2 (Figure 5D) only arose from
cultures which had received a Notch signal by means of ectopic
NICD1 expression, but not in empty vector transduced con-
trol cultures. With regard to dosage dependence, however, T cell
and ILC2 differentiation displayed opposite requirements: even
very low doses of Notch activity were sufficient to elicit develop-
ment of T-lineage cells (Figure 5C). In fact, the lowest levels of
NOTCH1 signaling activity, owing to the leakiness of our system
in the absence of Tamoxifen (see above), gave rise to the most
prominent T cell differentiation (almost 20% of CD4+CD8α+ T
cells), whereas hardly any ILC2 were observed in this condition
(Figure 5D). Titrating in Tamoxifen to induce higher levels of
NOTCH1 signaling gradually diminished the number of T cell
lineage cells obtained (Figure 5C). In contrast, stronger NOTCH1
induced more ILC2 differentiation (Figure 5D). Most strikingly,
the highest level of Notch signaling, induced here by constitutively
active NICD1, did not yield any T cells (Figure 5C); instead, con-
stitutive NICD1 expression resulted in the most prominent ILC2
differentiation (Figure 5D). Taken together, these results demon-
strate that by varying signal strength, one and the same Notch
pathway can activate two distinct differentiation programs, with
weaker signals favoring development of T cells and stronger signals
inducing more efficient ILC2 differentiation.
DISCUSSION
ILC are increasingly recognized as important mediators of immu-
nity and lymphoid tissue (re)modeling (2). The mechanisms
underlying differentiation of these cells and the anatomical loca-
tions where these processes take place are only beginning to
be characterized. What is known has mostly been learned from
studies in mice. Here, we have studied the differentiation of
human ILC2.
We report the identification of ILC2 in the human thymus. The
presence of ILC2 in the thymus could theoretically be explained
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FIGURE 5 | Notch promotes differentiation ofT cells versus ILC2 in a
signal strength dependent manner. (A) Activation of the
Notch-responsive reporter constructs HES1-luciferase (left) and
CBF-1-luciferase (right) induced by different levels of nuclear release of
mER-NICD1 or constitutive NICD1 expression. U2OS cells were
transfected with a mixture of reporter plasmids expressing Firefly
luciferase, a plasmid constitutively expressing Renilla luciferase and an
empty vector control, mER-NICD or NICD1, respectively.
4-Hydroxytamoxifen (Tamoxifen, 4-HT) was added at the indicated
concentrations. Firefly luciferase activities were normalized to Renilla
luciferase activities from the same samples and are displayed as fold of
empty vector control samples at the respective concentration of
Tamoxifen. Data shown are from one representative of three independent
experiments performed in triplicate (mean+SD). (B–D) Flow cytometric
analysis of thymocytes after 2 weeks of co-culture on control OP9 cells.
CD34+CD1a− progenitors were transduced with NICD1, mER-NICD1, or
an empty vector control prior to co-culture. Tamoxifen was added to
mER-NICD1 and empty vector transduced cultures at the concentrations
indicated. (B) Levels of CD7 expression are displayed as MFI. Data shown
are from one representative experiment from 2 similar experiments.
(C)Transduced cells were analyzed for surface expression of CD4 and CD8
to assess T cell differentiation. (D) ILC2 differentiation as determined by
expression of CRTH2 on transduced lineage− cells. Data displayed in (C)
and (D) are cumulative from three independent experiments (mean+SD).
by migration to this site, although it is not clear what the function
of such recruitment would be. The currently known function of
ILC2 consists of defense at epithelial barriers (58) and it seems
unlikely that ILC2 would be required for this purpose in a ster-
ile internal organ such as the thymus. It is of course conceivable
that ILC2 have additional, not identified functions, for instance
in tissue homeostasis or development, which explain their pres-
ence in this organ. An alternative explanation for their presence
in the thymus is that ILC2 are in fact generated in this organ,
although the thymus is likely not the only site of ILC2 develop-
ment. At face value, a role for the thymus in differentiation of ILC2
may seem at odds with a study reporting the identification of a
Lin−Sca1hiId2hi GATA3hi (LSIG) ILC2 precursor in murine bone
marrow (20, 32). However, transcriptome analysis and adoptive
transfer experiments suggested that these cells have already com-
mitted to the ILC2 lineage and may represent an immature ILC2
stage. Whether differentiation of progenitors into this immature
ILC2 stage could also take place in the thymus was not addressed
directly in these studies. Another mouse study directly addressed
the question whether the thymus is essential for ILC2 develop-
ment (23). Wong and colleagues made use of FoxN1nu/nu (nude)
mice, which display defective thymus development (59). Normal
numbers of group 2 ILC were found in mesenteric lymph nodes in
these mice after injection of IL-25 (23). While this formally proves
that ILC2 differentiation can occur at extrathymic sites, at least in
mice, this study does not address whether this process also occurs
in the thymus.
Whether ILC2 differentiation occurs in the human thymic
organoid could be investigated using humanized immune system
mice (60). Furthermore, studies of patients with DiGeorge syn-
drome, who have defects in thymic development like FoxN1nu/nu
(nude) mice (61), could provide valuable insights. However, it
stands to reason that, if ILC2 do develop in the thymus, progeni-
tors with the capacity to differentiate into group 2 ILC must exist
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in this organ. Our finding that CD34+CD1a− cells differentiate
into ILC2 in response to activation of Notch shows that this is
indeed the case.
Recent studies underline the close genetic relationship between
T and ILC2 cells, the latter expressing a multitude of mark-
ers which classically have been considered T-lineage genes, such
as CD7, Lck, Lat, Bcl11b, and Tcf7 (6, 35). Indeed, thymic
lineage−CD34+CD1a− cells can develop into both ILC2 and T
cells, as we show here. Expression of CD1a by these cells has been
considered to mark their commitment to the T cell lineage (43).
Correspondingly, we found that CD34+CD1a+ progenitors failed
to give rise to ILC2 after co-culture on OP9 Dll1. However, the
ability to differentiate into ILC2 was not lost completely by these
cells, as ectopic expression of the NICD1, which we found to be
a much stronger stimulus for ILC2 differentiation than OP9 Dll1
cells, could still divert these cells into ILC2. A gradual decrease
in ILC2 potential was reported also for murine progenitors: ILC2
differentiation in vitro was induced efficiently by OP9 Dll1 when
CD44+CD25−CD4−CD8− double negative 1 (DN1) cells were
used, less efficiently when using CD44+CD25+ DN2 cells, and
not at all with CD44−CD25+ DN3 cells (23), which are thought
to be fully committed to the T cell lineage (62).
Many studies have shown that thymic CD34+CD1a− cells dif-
ferentiate into T cells when cultured on OP9 stroma cells express-
ing the Notch ligand Dll1 (46, 63). It was surprising, therefore,
that differentiation of ILC2 was also obtained using the same con-
ditions and progenitors in our experiments. Our data reveal that
the strength of the Notch signal is an important parameter in
this decision, with lower Notch signals mediating T cell differ-
entiation, while strong Notch signals induce ILC2 differentiation.
Similar dosage dependent outcomes of Notch signaling have been
reported before (64), for instance in the lineage decision between
αβ and γδ T cells (52, 65). While we did not observe γδ T cells
in our cultures, possibly due to differences in culture conditions
and progenitor sort strategies, the block in αβ T cell develop-
ment observed here with high levels of Notch activation is in
line with these studies (65). Two non-mutually exclusive mech-
anisms can be envisioned to explain how a subset of progenitor
cells receives the strong Notch signals required for differentiation
of ILC2. First, specialized niches with high levels of Notch lig-
ands may exist in the thymus and/or hematopoietic organs (66,
67). Both cortical and medullary epithelial cells (TEC) express the
Notch ligands Dll1, Dll4, Jag1 and Jag2 in humans (66). How-
ever, other components of the thymic stroma, for instance thymic
DCs (68), also express Notch ligands. Second, the CD34+CD1a−
population may contain a mixture of cells with high and low
sensitivity to Notch ligands. Such differential sensitivity may for
instance be achieved through modification by Fringe glycosylases,
expression of different levels of Notch and downstream media-
tors or pathway modifiers (69, 70). This diversification may itself
be influenced by factors produced in specialized niches. Indeed,
factors such as TGFβ, Wnt, and type I interferons can all mod-
ify the maximum amplitude of Notch signaling through various
ways (64) (Amsen, unpublished data). TECs produce TGFβ (71),
while thymic plasmacytoid DCs constitutively express IFNα under
non-inflamed conditions (72), indicating once more that both
epithelial and non-epithelial stromal components of the thymic
microenvironment might contribute to specialized niches capable
of eliciting strong Notch signals in developing thymocytes. Given
that mice lacking thymic epithelial cells still generate ILC2 (23),
it is tempting to speculate that the relevant source of the Notch
activating signals consists of a non-epithelial stromal cell.
The prominent induction of ILC2 differentiation by strong
Notch signaling echoes a similar role for Notch in differentiation
of T helper 2 cells, which are functionally related to ILC2 (73).
Induction of Th2 differentiation by Notch involves direct transac-
tivation of GATA3 in CD4+ T cells (31, 50, 51). Since GATA3 is also
essential for the generation and function of murine and human
ILC2 (32, 33), it seemed likely that Notch mediated ILC2 differenti-
ation would also proceed via induction of this transcription factor,
at least partially. To our surprise, however, GATA3 levels were not
elevated by Notch signaling during differentiation of ILC2 cells
from CD34+CD1a− cells. Although not elevated, GATA3 expres-
sion was still clearly detectable in these cells, suggesting that Notch
mediated ILC2 development might not be completely indepen-
dent of GATA3. Nonetheless, it seems likely that Notch induces
the ILC2 fate predominantly via activation of other genes. Inter-
estingly, some of the genes shared between the T cell and ILC2
programs (6, 35), Tcf1 and Bcl11b, are established direct targets of
Notch (74, 75). Direct transactivation of such genes would provide
at least a partial explanation for the ability of Notch to induce ILC2
differentiation without elevating expression of GATA3, although
it seems likely that also other direct Notch targets exist, which are
dedicated to the ILC2 differentiation program. One mechanistic
explanation for the high Notch signal strength dependence of ILC2
differentiation might be that transactivation of such dedicated tar-
get genes requires higher concentrations of NICD, for instance due
to steric impediment by factors surrounding the Notch-responsive
elements.
In summary, we show that the human thymus contains ILC2.
Whether or not this reflects a role for this organ in development
of these cells, progenitors with the capacity to differentiate into
ILC2 can be found in the thymus. These progenitors reside within
a population which also has the capacity to generate T cells in
response to apparently the same set of signals and we demonstrate
that the strength of Notch signaling is an important determinant in
deciding which fate is chosen. Apart from augmenting our under-
standing of the processes involved in the generation of ILC2, these
findings also suggest possible avenues to generate ILC2 for recon-
stitution of this cell type in patients after stem cell transplantation
or in patients suffering from immunodeficiencies.
MATERIALS AND METHODS
ISOLATION OF THYMIC HEMATOPOIETIC PROGENITORS
Postnatal thymic (PNT) tissue specimens were obtained from chil-
dren undergoing open heart surgery (LUMC, Leiden, The Nether-
lands); their use was approved by the AMC ethical committee in
accordance with the declaration of Helsinki. Cell suspensions were
prepared by mechanical disruption using the Stomacher 80 Bio-
master (Seward). After overnight incubation at 4°C, thymocytes
were isolated from a Ficoll-Hypaque (Lymphoprep; Nycomed
Pharma) density gradient. Single cell suspensions were enriched
for CD34+ cells by MACS (Miltenyi Biotec), stained with fluores-
cently labeled antibodies and subsequently FACS sorted on a FACS
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Aria (BD Bioscience) as CD34+CD1a−CD3−CD56−BDCA2− or
CD34+CD1a+CD3−CD56−BDCA2−, respectively (referred to in
this study as CD34+CD1a− and CD34+CD1a+). Purity of the
sorted populations was >99%.
FLOW CYTOMETRY
Staining for expression of surface proteins was performed at
4°C for 20 min. Distinction of live and dead cells was based
on staining with 7-Aminoactinomycin D (7-AAD, eBiosciences)
or fixable live/dead dyes (Invitrogen). Data were acquired on a
LSR Fortessa flow cytometer (BD Bioscience) and analyzed using
FlowJo software (TreeStar). Single cell suspensions were stained
with antibodies directly labeled with Fluorescein Isothiocyanate
(FITC), Phycoerythrin (PE), Phycoerythrin-Cyanine 5 (PE-Cy5),
PE-Cy5.5, PE-Cy7, PerCP-Cy5.5, Allophycocyanin (APC)/Alexa
Fluor 647, APC-Cy7, AF700 (all BD Bioscience, BioLegend, or
MACS Miltenyi), Horizon V500 (HV500, BD Bioscience), Brilliant
Violet 421 (BV421), BV711, and BV785 (all BioLegend). Antibod-
ies specific for the following human antigens were used: CD1a,
CD3, CD4, CD7, CD8, CD11c, CD14, CD19, CD25, CD34, CD45,
CD56, CD94, CD117 (cKit), CD123, CD127 (IL7Rα), CD161,
CD294 (CRTH2), CD303 (BDCA2), CD336 (Nkp44), CD278
(ICOS), TCRαβ, TCRγδ, and FceR1. Anti-mouse CD90.1 (Thy1.1)
-FITC, -PE, or -APC-eFluor 780 (eBioscience) were used to detect
cells transduced with MSCV – IRES-Thy1.1 retroviruses.
RETROVIRAL CONSTRUCTS
The human NICD1-IRES-Thy1.1-MSCV construct has been
described before (49). To generate the mER-NICD fusion, an
N-terminal mER domain was PCR amplified using the follow-
ing primers: GATCAGGAATTCCACACCATGGGAGATCCACG
AAATGAA and GATCAGGATATCCACCTTCCTCTTCTTCTTGG
and cloned into the EcOR1 and EcORV sites of pBluescript
(pBS) to create mER-pBS. Human NICD1 lacking a translation
initiation signal was PCR amplified using these primers: ATCG-
GAGGTTCTCGCAAGCGCCGGCGGCAGCAT and GATCA-
GAAGCTTGAATTCTTACTTGAAGGCCTCCGGAATG and sub-
sequently cloned into the EcORV and HindIII sites of mER-pBS.
The mER-NICD1 fusion insert was then cloned into IRES-Thy1.1-
MSCV using BamH1 and Cla1.
VIRUS PRODUCTION AND TRANSDUCTION
For virus production, Phoenix GALV packaging cells were tran-
siently transfected using FuGene HD (Promega). Virus containing
supernatant was harvested 48 h after transfection, snap frozen
on dry ice and stored at −80°C until use. For transduction,
cells were incubated with virus supernatant in plates coated with
Retronectin (30µg/ml, Takara Biomedicals) for 6–8 h at 37°C the
following day.
IN VITRO DIFFERENTIATION OF THYMIC PROGENITORS
Sorted thymic progenitors were cultured overnight in Yssel’s
medium containing 5% normal human serum, SCF (20 ng/ml),
and IL-7 (10 ng/ml, both PeproTech). OP9 cells were mitotically
inactivated by irradiation with 30 Grey and seeded at a density of
5× 103/cm2 1 day prior to initiation of co-cultures. After trans-
duction, thymic progenitors were added to pre-seeded OP9 cells.
Co-cultures were performed in MEMα (Invitrogen) with FCS
(20%, FetalClone I, Hyclone) and IL-7 (5 ng/ml). In some cases,
Flt3l (5 ng/ml, PeproTech) was added to the medium. Cultures
were refreshed every 3–4 days. Differentiation assays for ILCs were
typically analyzed after 1 week, unless stated otherwise. Cells were
harvested by forceful pipetting and passed through 70µm nylon
mesh filters (Spectrum Labs). For longer culture periods, cells were
transferred onto fresh stromal cells every week.
QUANTITATIVE REAL-TIME PCR
RNA was isolated using the NucleoSpin RNA II or NucleoSpin
RNA XS kit (Macherey-Nagel) according to the manufacturer’s
instructions. cDNA synthesis was done using the High Capac-
ity cDNA kit (Applied Biosystems). Quantitative Real-Time PCRs
were performed in an iCycler instrument using IQ SYBR Green
Supermix (both BioRad). For calculation of relative expression
level of the genes of interest, the ∆Ct method was used. The fol-
lowing primers were used: ACTB (β-Actin) (Gene ID: 60) Forward:
CAC CAT TGG CAA TGA GCG GTT C; Reverse: AGG TCT TTG
CGG ATG TCC ACG T; CRLF2 (TSLP-R) (Gene ID: 64109) For-
ward: GAG TGG CAG TCC AAA CAG GAA; Reverse: ACA TCC
TCC ATA GCC TTC ACC; GATA3 (Gene ID: 2625) Forward: ACC
ACA ACC ACA CTC TGG AGG A; Reverse: TCG GTT TCT GGT
CTG GAT GCC T; IL1RL1 (ST2) (Gene ID: 9173) Forward: ATG
TTC TGG ATT GAG GCC AC; Reverse: GAC TAC ATC TTC TCC
AGG TAG CAT; IL-5 (Gene ID: 3567) Forward: AGC TGC CTA
CGT GTA TGC CA; Reverse: CAG GAA CAG GAA TCC TCA GA;
IL-13 (Gene ID: 3596) Forward: ATT GCT CTC ACT TGC CTT
GG; Reverse: GTC AGG TTG ATG CTC CAT ACC; IL17RB (Gene
ID: 55540) Forward: CCA ACA CAG CAC TAT CAT CG; Reverse:
ATA TGG AGT CAG CTG CAC CG; PTGDR2 (CRTH2) (Gene ID:
11251) Forward: AAT CCT GTG CTC CCT CTG TG; Reverse: ATG
TAG CGG ATG CTG GTG TT; RORA (Gene ID: 6095) Forward:
ACA AGC AGC GGG AGG TGA TGT; Reverse: TGA GAG TCA
AAG GCA CGG C.
REPORTER GENE ASSAYS
U2OS cells were transiently transfected using the FuGene HD
transfection reagent (Promega). Cells were co-transfected with a
NOTCH-responsive promoter and either NICD1-IRES-Thy1.1-
MSCV, mER-NICD1-Thy1.1-MSCV, or an empty vector control.
To correct for differences in transfection efficiency, the pRL-CMV
control vector was co-transfected, from which Renilla luciferase is
expressed constitutively. Transfections were performed in tripli-
cate. Where applicable, 4-Hydroxy-Tamoxifen (Sigma) was added
after overnight incubation to induce nuclear translocation of
mER-NICD1. Cells were lysed 48 h post transfection and luciferase
activity was measured using the Dual Luciferase Reporter Assay
System (Promega) on a Synergy HT microplate reader (Syntek).
Two different Notch-responsive reporter constructs were used,
which have been described previously (76).
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